Duralax5 mg

Duralax is a stimulant laxative used in the following situations:

Established / labeled uses

• Occasional (short-term) constipation: Duralax is indicated for the short-term relief of occasional constipation, when a rapid, predictable bowel movement is needed.
• Bowel evacuation before procedures: Duralax is widely used as part of a bowel-preparation regimen before colonoscopy, sigmoidoscopy, abdominal x-ray, surgery, or other procedures requiring an empty bowel.

Adjunct / regimen use

• Duralax is frequently combined with other bowel-preparation agents (e.g., polyethylene glycol-based solutions) as part of a multi-step protocol; in this role it is an adjunct to the primary preparation, not a stand-alone bowel-prep solution.
• Duralax is also used in the management of chronic constipation associated with opioid use or in patients unresponsive to bulk-forming/osmotic laxatives, under medical supervision, when other measures have failed.

Duralax is not intended for routine, prolonged, or unsupervised daily use. Persistent constipation lasting more than one week should be medically evaluated rather than self-treated.

Each enteric-coated oral tablet contains Bisacodyl 5 mg.

Bisacodyl is also formulated as a rectal suppository containing Bisacodyl 10 mg.

Exact excipients and strengths vary by manufacturer/brand; refer to the specific product label.

Duralax is a synthetic, orally and rectally administered stimulant (contact) laxative belonging to the diphenylmethane (triarylmethane) chemical class. It is used to produce a bowel movement in occasional constipation and to empty the bowel before diagnostic or surgical procedures.

Oral tablets of Duralax are enteric-coated so that the drug is released in the colon rather than the stomach, minimizing gastric irritation and unpredictable onset. The suppository form acts more rapidly by direct local stimulation of the rectal mucosa.

Stimulant (contact) laxative — Duralax belongs to the diphenylmethane/triarylmethane class of laxatives.

Mechanism

Bisacodyl is a prodrug that, after oral ingestion, is hydrolyzed by intestinal mucosal and bacterial enzymes to its active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM). BHPM directly stimulates sensory nerve endings in the colonic mucosa, triggering increased colonic peristaltic contractions. It also alters fluid and electrolyte transport, promoting accumulation of water and electrolytes within the colonic lumen, which softens the stool and increases its volume.

Onset

Oral Bisacodyl tablets typically produce a bowel movement within 6–12 hours. Rectal Bisacodyl suppositories act more quickly, usually within 15–60 minutes, because of direct local mucosal stimulation.

Absorption

Systemic absorption of Bisacodyl and its active metabolite is minimal; the drug acts predominantly through a local effect on the colon.

Take oral Duralax tablets whole with a full glass of water; do not crush or chew. Avoid taking Duralax within 1 hour before or after milk, antacids, or other agents that raise gastric pH, as this can dissolve the enteric coating prematurely and cause stomach irritation or cramping. Duralax oral tablets are commonly taken at bedtime for a morning bowel movement.

Duralax rectal suppositories should be inserted as far as possible into the rectum and retained for 15–30 minutes if possible before the urge to evacuate is allowed to occur.

• Milk, antacids, and acid-reducing agents (H2-blockers, proton pump inhibitors): Taking these within about 1 hour of oral Duralax can prematurely dissolve its enteric coating, releasing the drug in the stomach and causing gastric irritation, cramping, or reduced effectiveness.
• Diuretics and corticosteroids: Concurrent use with Duralax, especially with excessive or prolonged Duralax use, increases the risk of electrolyte disturbances (particularly hypokalemia).
• Digoxin: Duralax-induced hypokalemia from excessive/prolonged use can increase the risk of digoxin toxicity.

Common

• Abdominal cramping or pain
• Diarrhea
• Nausea
• Rectal burning or local irritation (with suppository use)

Less common / with excessive or prolonged use

• Dizziness or lightheadedness
• Electrolyte disturbances (e.g., hypokalemia) — see Precautions and Warnings
• Rectal bleeding
• Allergic reactions (rash, itching)

Seek medical attention if rectal bleeding occurs or if there is no bowel movement after using Duralax, as this may indicate a more serious underlying condition.

Pregnancy: Duralax is minimally absorbed systemically. It should be used during pregnancy only if clearly needed, and only after consulting a physician, as with any medication in pregnancy; non-pharmacologic measures and bulk-forming laxatives are generally preferred first-line options for constipation in pregnancy. Duralax should not be used routinely or for prolonged periods without medical supervision.

Lactation: Because systemic absorption of Duralax is minimal, clinically significant transfer into breast milk is not expected; however, Duralax should still be used during breastfeeding only if clearly needed and under medical advice.

• Duralax is intended for short-term, occasional use only; do not use for more than 7 consecutive days unless directed by a physician. Chronic stimulant laxative use has been associated with dependence-type effects on normal bowel function and electrolyte disturbances — persistent constipation warrants medical evaluation rather than continued self-treatment.
• Swallow oral tablets whole; do not crush, chew, or take within 1 hour of milk or antacids, as this can disrupt the enteric coating and cause premature release with stomach irritation or cramping (see Interactions).
• Use with caution in patients with rectal bleeding of unknown origin, inflammatory bowel disease, or a history suggestive of appendicitis or acute abdominal conditions; stop use and seek medical advice if severe abdominal pain, cramping, or rectal bleeding occurs.
• Excessive or prolonged use can cause electrolyte disturbances (particularly hypokalemia); use particular caution in patients on diuretics, corticosteroids, or digoxin.
• Use in children should be guided by a pediatrician for appropriate dosing and indication.
• Discontinue and consult a physician if no bowel movement occurs after use, or if abdominal pain persists, as this may suggest a serious underlying condition rather than simple constipation.

Overdose or excessive use of Duralax can cause severe diarrhea, abdominal cramping, and significant fluid and electrolyte loss (including dehydration and hypokalemia). If overdose of Duralax is suspected, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment. Management is supportive, focused on fluid and electrolyte replacement under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: No specific dose adjustment for Duralax is well established; systemic absorption is minimal, but use with the usual short-term-use precautions.
• Hepatic impairment: No specific dose adjustment for Duralax is well established given its predominantly local action and minimal systemic absorption.
• Elderly: Use Duralax with caution, particularly the rectal form, and monitor for electrolyte disturbance with repeated use; age-related comorbidities warrant closer supervision.
• Children: Use of Duralax in children should always be guided by a pediatrician for appropriate dosing and indication (see Pediatric Uses).

Duralax is intended for short-term or occasional use — typically single doses as needed, and not for more than 7 consecutive days without medical supervision. For bowel preparation, Duralax is used as a single dose or short course per the specific procedure protocol. Continuous, long-term self-administration of Duralax is not recommended; persistent constipation should be medically evaluated.

Stimulant laxatives (diphenylmethane/triarylmethane derivatives)

Bisacodyl is hydrolyzed in the intestine to its active metabolite, which directly stimulates sensory nerve endings in the colonic mucosa. This stimulation increases colonic motility (peristalsis) and promotes accumulation of water and electrolytes in the colonic lumen, resulting in softer stool and a bowel movement.

Oral Duralax is not generally recommended for children under 6 years of age except under direct physician guidance. In children 6–11 years, a lower oral dose (5 mg once daily) may be used under adult/physician supervision. Rectal Duralax suppositories may be used in children 2–11 years at a reduced dose (5 mg) under pediatrician guidance. Safety and efficacy of Duralax in children under 2 years have not been established, and use in this age group should only occur on a physician's specific direction. In all pediatric use, Duralax should be limited to short-term, occasional constipation and bowel-preparation indications, with dosing guided by a pediatrician.